NCT07523438 Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery
| NCT ID | NCT07523438 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexandria University |
| Condition | Dexmedetomidine |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-03-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-03-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg
Eligibility Criteria
Inclusion Criteria: * Age: 3-6 years, both sexes * ASA physical status class I , II. Exclusion Criteria: * history of neurological and psychiatric disease * body mass index \> 20 kg m-2 * allergy to dexmedetomidine * patients on medical treatment which has any sedative effect * mentally retarded children
Contact & Investigator
sarah m elgamal, MD
PRINCIPAL INVESTIGATOR
Alexandria University
Frequently Asked Questions
Who can join the NCT07523438 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 6 Years, studying Dexmedetomidine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07523438 currently recruiting?
Yes, NCT07523438 is actively recruiting participants. Contact the research team at sarahelgamal1990@yahoo.com for enrollment information.
Where is the NCT07523438 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07523438 clinical trial?
NCT07523438 is sponsored by Alexandria University. The principal investigator is sarah m elgamal, MD at Alexandria University. The trial plans to enroll 120 participants.